Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Eiger BioPharmaceuticals, Inc.EIGR · Entity 16554 | Director | March 01, 2023 | March 04, 2023 |
| VERTEX PHARMACEUTICALS INC / MAVRTX · Entity 2875 | EVP Chief Patient & Ext Af Off | July 21, 2026 | July 23, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Eiger BioPharmaceuticals, Inc.
Report date March 01, 2023 · Filed March 04, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.71 · Expires 2033-02-28 | Direct | 28,000 |
Reported balance
After 2023-03-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-03-01 · Grant · Acquired 28,000 · Balance 28,000 F1: The option vests in equal monthly installments over 12 months measured from March 1, 2023, subject to Reporting Person's continuous service status as of each such date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests in equal monthly installments over 12 months measured from March 1, 2023, subject to Reporting Person's continuous service status as of each such date.
VERTEX PHARMACEUTICALS INC / MA
Report date July 21, 2026 · Filed July 23, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 66,512 |
Reported balance
After 2026-07-21 transaction · row 1
1 source rowRow 1 · 2026-07-21 · Grant · Acquired 8,251 · Balance 66,512 F1: Restricted stock unit award that vests on 03/31/2030. |
| Common StockSEC Table I · non-derivative | Indirect401(k) | 882 |
Reported balance
Holding disclosure · report date 2026-07-21 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 882 |
| Common StockSEC Table I · non-derivative | IndirectHeld in Trust | 6,637 |
Reported balance
Holding disclosure · report date 2026-07-21 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 6,637 |
Filing footnotes · ownership attribution and instrument terms
F1: Restricted stock unit award that vests on 03/31/2030.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 04, 2019 Filed Nov 6, 2019 21:15 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 1,100 | $201.10 | $221,210.00 |
DisclosureSEC source: 0001209191-19-055470 · doc4.xml · nonDerivative · entry 5 Sachdev Amit · CIK 0001406338 · EVP, Chief Patient Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,416 F1 · kind: Transaction made pursuant to Mr. Sachdev's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Sachdev undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $201.10 (range $200.86 to $201.26). Read SEC document |
| November 04, 2019 Filed Nov 6, 2019 21:15 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 2,497 | $200.12 | $499,699.64 |
DisclosureSEC source: 0001209191-19-055470 · doc4.xml · nonDerivative · entry 4 Sachdev Amit · CIK 0001406338 · EVP, Chief Patient Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,516 F1 · kind: Transaction made pursuant to Mr. Sachdev's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Sachdev undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $200.12 (range $199.83 to $200.53). Read SEC document |
| November 04, 2019 Filed Nov 6, 2019 21:15 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 500 | $199.77 | $99,885.00 |
DisclosureSEC source: 0001209191-19-055470 · doc4.xml · nonDerivative · entry 3 Sachdev Amit · CIK 0001406338 · EVP, Chief Patient Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,013 F1 · kind: Transaction made pursuant to Mr. Sachdev's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $199.77 (range $199.76 to $199.79). F3 · price: Mr. Sachdev undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| November 04, 2019 Filed Nov 6, 2019 21:15 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 1,942 | $86.52 | $168,021.84 |
DisclosureSEC source: 0001209191-19-055470 · doc4.xml · nonDerivative · entry 2 Sachdev Amit · CIK 0001406338 · EVP, Chief Patient Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,513 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 04, 2019 Filed Nov 6, 2019 21:15 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 2,155 | $91.05 | $196,212.75 |
DisclosureSEC source: 0001209191-19-055470 · doc4.xml · nonDerivative · entry 1 Sachdev Amit · CIK 0001406338 · EVP, Chief Patient Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,571 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 25, 2019 Filed Oct 29, 2019 20:54 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (Right to Buy) · Derivative | 4,311 | $0.00 Strike: $91.05 | $0.00 |
DisclosureSEC source: 0001209191-19-054333 · doc4.xml · derivative · entry 5 Sachdev Amit · CIK 0001406338 · EVP, Chief Patient Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,311 Underlying: Common Stock · 4,311 shares Expires 2026-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option vests in 16 quarterly installments from 02/02/2016. Read SEC document |
| October 25, 2019 Filed Oct 29, 2019 20:54 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 4,311 | $195.01 | $840,688.11 |
DisclosureSEC source: 0001209191-19-054333 · doc4.xml · nonDerivative · entry 2 Sachdev Amit · CIK 0001406338 · EVP, Chief Patient Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,416 F1 · kind: Transaction made pursuant to Mr. Sachdev's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $195.01 (range $195.00 to $195.04). F3 · price: Mr. Sachdev undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| October 25, 2019 Filed Oct 29, 2019 20:54 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 4,311 | $91.05 | $392,516.55 |
DisclosureSEC source: 0001209191-19-054333 · doc4.xml · nonDerivative · entry 1 Sachdev Amit · CIK 0001406338 · EVP, Chief Patient Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,727 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 22, 2019 Filed Oct 24, 2019 23:28 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,883 | $0.00 Strike: $86.52 | $0.00 |
DisclosureSEC source: 0001209191-19-053945 · doc4.xml · derivative · entry 5 Sachdev Amit · CIK 0001406338 · EVP, Chief Patient Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,650 Underlying: Common Stock · 3,883 shares Expires 2027-02-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option vests in 16 quarterly installments from 02/03/2017. Read SEC document |
| October 22, 2019 Filed Oct 24, 2019 23:28 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 3,883 | $190.27 | $738,818.41 |
DisclosureSEC source: 0001209191-19-053945 · doc4.xml · nonDerivative · entry 2 Sachdev Amit · CIK 0001406338 · EVP, Chief Patient Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,416 F1 · kind: Transaction made pursuant to Mr. Sachdev's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $190.27 (range $190.00 to $190.60). F3 · price: Mr. Sachdev undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| October 22, 2019 Filed Oct 24, 2019 23:28 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 3,883 | $86.52 | $335,957.16 |
DisclosureSEC source: 0001209191-19-053945 · doc4.xml · nonDerivative · entry 1 Sachdev Amit · CIK 0001406338 · EVP, Chief Patient Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,299 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 30, 2019 Filed May 30, 2019 21:38 UTC | Eiger BioPharmaceuticals, Inc. EIGR · Entity 16554 | GrantStock Option ( Right to Buy) · Derivative | 25,000 | $0.00 Strike: $11.13 | $0.00 |
DisclosureSEC source: 0001209191-19-033500 · doc4.xml · derivative · entry 1 Sachdev Amit · CIK 0001406338 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2029-05-29 F1 · derivative.exercise_date: The option vests in equal monthly installments over 36 months measured from May 30, 2019 subject to Reporting Person's continuous service status as of each such date. Read SEC document |
| May 15, 2019 Filed May 17, 2019 20:37 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 61 | $165.41 | $10,090.01 |
DisclosureSEC source: 0001209191-19-030966 · doc4.xml · nonDerivative · entry 1 Sachdev Amit · CIK 0001406338 · EVP, CRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,416 F1 · kind: Transaction made pursuant to Mr. Sachdev's company-approved trading plan under Rule 10b5-1. Read SEC document |
| February 11, 2019 Filed Feb 13, 2019 21:40 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 100 | $182.05 | $18,205.00 |
DisclosureSEC source: 0001209191-19-009667 · doc4.xml · nonDerivative · entry 4 Sachdev Amit · CIK 0001406338 · EVP, CRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,165 F1 · kind: Transaction made pursuant to Mr. Sachdev's company approved trading plan under Rule 10b5-1. Read SEC document |
| February 11, 2019 Filed Feb 13, 2019 21:40 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 5,406 | $180.85 | $977,675.10 |
DisclosureSEC source: 0001209191-19-009667 · doc4.xml · nonDerivative · entry 3 Sachdev Amit · CIK 0001406338 · EVP, CRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,265 F1 · kind: Transaction made pursuant to Mr. Sachdev's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Sachdev undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $180.85 (range $180.65 to $181.63). Read SEC document |
| February 11, 2019 Filed Feb 13, 2019 21:40 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 19,021 | $180.17 | $3,427,013.57 |
DisclosureSEC source: 0001209191-19-009667 · doc4.xml · nonDerivative · entry 2 Sachdev Amit · CIK 0001406338 · EVP, CRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,671 F1 · kind: Transaction made pursuant to Mr. Sachdev's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Sachdev undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $180.17 (range $179.64 to $180.64). Read SEC document |
| February 11, 2019 Filed Feb 13, 2019 21:40 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 10,568 | $179.44 | $1,896,321.92 |
DisclosureSEC source: 0001209191-19-009667 · doc4.xml · nonDerivative · entry 1 Sachdev Amit · CIK 0001406338 · EVP, CRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,692 F1 · kind: Transaction made pursuant to Mr. Sachdev's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $179.44 (range $178.61 to $179.61). F3 · price: Mr. Sachdev undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| February 06, 2019 Filed Feb 8, 2019 21:51 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantStock Option (Right to Buy) · Derivative | 25,026 | $0.00 Strike: $187.53 | $0.00 |
DisclosureSEC source: 0001209191-19-008592 · doc4.xml · derivative · entry 6 Sachdev Amit · CIK 0001406338 · EVP, CRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,026 Underlying: Common Stock · 25,026 shares Expires 2029-02-05 F4 · derivative.exercise_date: The option vests in 16 quarterly installments from 2/6/2019. Read SEC document |
| February 06, 2019 Filed Feb 8, 2019 21:51 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 9,799 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-008592 · doc4.xml · nonDerivative · entry 3 Sachdev Amit · CIK 0001406338 · EVP, CRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,260 F3 · shares: Restricted stock unit award that vests in installments beginning on 2/24/2020. Read SEC document |
| February 06, 2019 Filed Feb 8, 2019 21:51 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 10,126 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-008592 · doc4.xml · nonDerivative · entry 2 Sachdev Amit · CIK 0001406338 · EVP, CRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,461 F2 · shares: Represents earned performance shares with respect to a performance stock unit award granted on 2/3/2018 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/6/2019. The earned performance shares will vest in installments beginning on 2/17/2019. Read SEC document |
| February 06, 2019 Filed Feb 8, 2019 21:51 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 17,298 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-008592 · doc4.xml · nonDerivative · entry 1 Sachdev Amit · CIK 0001406338 · EVP, CRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,335 F1 · shares: Represents earned performance shares with respect to a performance stock unit award granted on 2/2/2016 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/6/2019 and the shares will vest on 2/10/2019. Read SEC document |
| February 04, 2019 Filed Feb 6, 2019 21:51 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,155 | $91.05 Strike: $91.05 | $196,212.75 |
DisclosureSEC source: 0001209191-19-007776 · doc4.xml · derivative · entry 12 Sachdev Amit · CIK 0001406338 · EVP, CRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,622 Underlying: Common Stock · 2,155 shares Expires 2026-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F10 · derivative.exercise_date: The option vests in 16 quarterly installments from 2/2/2016. Read SEC document |
| February 04, 2019 Filed Feb 6, 2019 21:51 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,942 | $86.52 Strike: $86.52 | $168,021.84 |
DisclosureSEC source: 0001209191-19-007776 · doc4.xml · derivative · entry 11 Sachdev Amit · CIK 0001406338 · EVP, CRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,533 Underlying: Common Stock · 1,942 shares Expires 2027-02-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_date: The option vests in 16 quarterly installments from 2/3/2017. Read SEC document |
| February 04, 2019 Filed Feb 6, 2019 21:51 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 3,625 | $187.30 | $678,962.50 |
DisclosureSEC source: 0001209191-19-007776 · doc4.xml · nonDerivative · entry 8 Sachdev Amit · CIK 0001406338 · EVP, CRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,037 F1 · kind: Transaction made pursuant to Mr. Sachdev's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Sachdev undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F8 · price: Open market sales reported on this line occurred at a weighted average price of $187.30 (range $186.92 to $187.63). Read SEC document |
| February 04, 2019 Filed Feb 6, 2019 21:51 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 5,000 | $186.55 | $932,750.00 |
DisclosureSEC source: 0001209191-19-007776 · doc4.xml · nonDerivative · entry 7 Sachdev Amit · CIK 0001406338 · EVP, CRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,662 F1 · kind: Transaction made pursuant to Mr. Sachdev's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Sachdev undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F7 · price: Open market sales reported on this line occurred at a weighted average price of $186.55 (range $185.90 to $186.90). Read SEC document |
| February 04, 2019 Filed Feb 6, 2019 21:51 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 1,035 | $187.23 | $193,783.05 |
DisclosureSEC source: 0001209191-19-007776 · doc4.xml · nonDerivative · entry 6 Sachdev Amit · CIK 0001406338 · EVP, CRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,662 F1 · kind: Transaction made pursuant to Mr. Sachdev's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Sachdev undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F6 · price: Open market sales reported on this line occurred at a weighted average price of $187.23 (range $186.94 to $187.60). Read SEC document |
| February 04, 2019 Filed Feb 6, 2019 21:51 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 1,120 | $186.52 | $208,902.40 |
DisclosureSEC source: 0001209191-19-007776 · doc4.xml · nonDerivative · entry 5 Sachdev Amit · CIK 0001406338 · EVP, CRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,697 F1 · kind: Transaction made pursuant to Mr. Sachdev's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Sachdev undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $186.52 (range $185.90 to $186.89). Read SEC document |
| February 04, 2019 Filed Feb 6, 2019 21:51 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 2,155 | $91.05 | $196,212.75 |
DisclosureSEC source: 0001209191-19-007776 · doc4.xml · nonDerivative · entry 4 Sachdev Amit · CIK 0001406338 · EVP, CRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,817 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 04, 2019 Filed Feb 6, 2019 21:51 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 742 | $187.35 | $139,013.70 |
DisclosureSEC source: 0001209191-19-007776 · doc4.xml · nonDerivative · entry 3 Sachdev Amit · CIK 0001406338 · EVP, CRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,662 F1 · kind: Transaction made pursuant to Mr. Sachdev's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Sachdev undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $187.35 (range $187.03 to $187.59). Read SEC document |
| February 04, 2019 Filed Feb 6, 2019 21:51 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 1,200 | $186.57 | $223,884.00 |
DisclosureSEC source: 0001209191-19-007776 · doc4.xml · nonDerivative · entry 2 Sachdev Amit · CIK 0001406338 · EVP, CRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,404 F1 · kind: Transaction made pursuant to Mr. Sachdev's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $186.57 (range $185.99 to $186.90). F3 · price: Mr. Sachdev undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| February 04, 2019 Filed Feb 6, 2019 21:51 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 1,942 | $86.52 | $168,021.84 |
DisclosureSEC source: 0001209191-19-007776 · doc4.xml · nonDerivative · entry 1 Sachdev Amit · CIK 0001406338 · EVP, CRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,604 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 15, 2018 Filed Nov 19, 2018 22:34 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 61 | $163.75 | $9,988.75 |
DisclosureSEC source: 0001209191-18-059268 · doc4.xml · nonDerivative · entry 1 Sachdev Amit · CIK 0001406338 · EVP, CRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,662 F1 · kind: Transaction made pursuant to Mr. Sachdev's company-approved trading plan under Rule 10b5-1. Read SEC document |
| November 05, 2018 Filed Nov 6, 2018 21:45 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,941 | $0.00 Strike: $86.52 | $0.00 |
DisclosureSEC source: 0001209191-18-057421 · doc4.xml · derivative · entry 14 Sachdev Amit · CIK 0001406338 · EVP, CRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,475 Underlying: Common Stock · 1,941 shares Expires 2027-02-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_date: The option vests in 16 quarterly installments from 02/03/2017. Read SEC document |
| November 05, 2018 Filed Nov 6, 2018 21:45 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 428 | $174.41 | $74,647.48 |
DisclosureSEC source: 0001209191-18-057421 · doc4.xml · nonDerivative · entry 10 Sachdev Amit · CIK 0001406338 · EVP, CRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,662 F1 · kind: Transaction made pursuant to Mr. Sachdev's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Sachdev undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F7 · price: Open market sales reported on this line occurred at a weighted average price of $174.41(range $174.31 to $174.50). Read SEC document |
| November 05, 2018 Filed Nov 6, 2018 21:45 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 1,213 | $173.74 | $210,746.62 |
DisclosureSEC source: 0001209191-18-057421 · doc4.xml · nonDerivative · entry 9 Sachdev Amit · CIK 0001406338 · EVP, CRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,090 F1 · kind: Transaction made pursuant to Mr. Sachdev's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Sachdev undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F6 · price: Open market sales reported on this line occurred at a weighted average price of $173.74 (range $173.28 to $174.15). Read SEC document |
| November 05, 2018 Filed Nov 6, 2018 21:45 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 300 | $172.70 | $51,810.00 |
DisclosureSEC source: 0001209191-18-057421 · doc4.xml · nonDerivative · entry 8 Sachdev Amit · CIK 0001406338 · EVP, CRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,303 F1 · kind: Transaction made pursuant to Mr. Sachdev's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Sachdev undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $172.70 (range $172.16 to $173.12). Read SEC document |
| November 05, 2018 Filed Nov 6, 2018 21:45 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 1,941 | $86.52 | $167,935.32 |
DisclosureSEC source: 0001209191-18-057421 · doc4.xml · nonDerivative · entry 7 Sachdev Amit · CIK 0001406338 · EVP, CRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,603 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 02, 2018 Filed Nov 6, 2018 21:45 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,155 | $0.00 Strike: $91.05 | $0.00 |
DisclosureSEC source: 0001209191-18-057421 · doc4.xml · derivative · entry 13 Sachdev Amit · CIK 0001406338 · EVP, CRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,777 Underlying: Common Stock · 2,155 shares Expires 2026-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_date: The option vests in 16 quarterly installments from 2/2/2016. Read SEC document |
| November 02, 2018 Filed Nov 6, 2018 21:45 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 100 | $176.04 | $17,604.00 |
DisclosureSEC source: 0001209191-18-057421 · doc4.xml · nonDerivative · entry 6 Sachdev Amit · CIK 0001406338 · EVP, CRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,662 F1 · kind: Transaction made pursuant to Mr. Sachdev's company approved trading plan under Rule 10b5-1. Read SEC document |
| November 02, 2018 Filed Nov 6, 2018 21:45 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 100 | $175.31 | $17,531.00 |
DisclosureSEC source: 0001209191-18-057421 · doc4.xml · nonDerivative · entry 5 Sachdev Amit · CIK 0001406338 · EVP, CRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,762 F1 · kind: Transaction made pursuant to Mr. Sachdev's company approved trading plan under Rule 10b5-1. Read SEC document |
| November 02, 2018 Filed Nov 6, 2018 21:45 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 100 | $173.35 | $17,335.00 |
DisclosureSEC source: 0001209191-18-057421 · doc4.xml · nonDerivative · entry 4 Sachdev Amit · CIK 0001406338 · EVP, CRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,862 F1 · kind: Transaction made pursuant to Mr. Sachdev's company approved trading plan under Rule 10b5-1. Read SEC document |
| November 02, 2018 Filed Nov 6, 2018 21:45 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 1,255 | $172.81 | $216,876.55 |
DisclosureSEC source: 0001209191-18-057421 · doc4.xml · nonDerivative · entry 3 Sachdev Amit · CIK 0001406338 · EVP, CRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,962 F1 · kind: Transaction made pursuant to Mr. Sachdev's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Sachdev undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $172.81 (range $172.32 to $173.27). Read SEC document |
| November 02, 2018 Filed Nov 6, 2018 21:45 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 600 | $171.93 | $103,158.00 |
DisclosureSEC source: 0001209191-18-057421 · doc4.xml · nonDerivative · entry 2 Sachdev Amit · CIK 0001406338 · EVP, CRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,217 F1 · kind: Transaction made pursuant to Mr. Sachdev's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $171.93 (range $171.25 to $172.24). F3 · price: Mr. Sachdev undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| November 02, 2018 Filed Nov 6, 2018 21:45 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 2,155 | $91.05 | $196,212.75 |
DisclosureSEC source: 0001209191-18-057421 · doc4.xml · nonDerivative · entry 1 Sachdev Amit · CIK 0001406338 · EVP, CRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,817 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 03, 2018 Filed Aug 6, 2018 22:19 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,942 | $0.00 Strike: $86.52 | $0.00 |
DisclosureSEC source: 0001209191-18-045591 · doc4.xml · derivative · entry 14 Sachdev Amit · CIK 0001406338 · EVP, CRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,416 Underlying: Common Stock · 1,942 shares Expires 2027-02-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F11 · derivative.exercise_date: The option vests in 16 quarterly installments from 2/3/2017. Read SEC document |
| August 03, 2018 Filed Aug 6, 2018 22:19 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 100 | $176.69 | $17,669.00 |
DisclosureSEC source: 0001209191-18-045591 · doc4.xml · nonDerivative · entry 10 Sachdev Amit · CIK 0001406338 · EVP, CRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,662 F1 · kind: Transaction made pursuant to Mr. Sachdev's company-approved trading plan under Rule 10b5-1. Read SEC document |
| August 03, 2018 Filed Aug 6, 2018 22:19 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 700 | $175.86 | $123,102.00 |
DisclosureSEC source: 0001209191-18-045591 · doc4.xml · nonDerivative · entry 9 Sachdev Amit · CIK 0001406338 · EVP, CRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,762 F1 · kind: Transaction made pursuant to Mr. Sachdev's company-approved trading plan under Rule 10b5-1. F3 · price: Mr. Sachdev undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F9 · price: Open market sales reported on this line occurred at a weighted average price of $175.86 (range $175.57 to $176.30). Read SEC document |
| August 03, 2018 Filed Aug 6, 2018 22:19 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 1,142 | $174.50 | $199,279.00 |
DisclosureSEC source: 0001209191-18-045591 · doc4.xml · nonDerivative · entry 8 Sachdev Amit · CIK 0001406338 · EVP, CRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,462 F1 · kind: Transaction made pursuant to Mr. Sachdev's company-approved trading plan under Rule 10b5-1. F3 · price: Mr. Sachdev undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F8 · price: Open market sales reported on this line occurred at a weighted average price of $174.50 (range $174.17 to $175.07). Read SEC document |
| August 03, 2018 Filed Aug 6, 2018 22:19 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 1,942 | $86.52 | $168,021.84 |
DisclosureSEC source: 0001209191-18-045591 · doc4.xml · nonDerivative · entry 7 Sachdev Amit · CIK 0001406338 · EVP, CRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,604 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 02, 2018 Filed Aug 6, 2018 22:19 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,155 | $0.00 Strike: $91.05 | $0.00 |
DisclosureSEC source: 0001209191-18-045591 · doc4.xml · derivative · entry 13 Sachdev Amit · CIK 0001406338 · EVP, CRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,932 Underlying: Common Stock · 2,155 shares Expires 2026-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F10 · derivative.exercise_date: The option vests in 16 quarterly installments from 2/2/2016. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.